SICHUAN GOLDSTONE ASIA PHARMACEUTICAL INC.

Sichuan Goldstone Asia Pharmaceutical Inc.

300434

CNE100001YX5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
8.95 ^CNY	-1.10%		-1.00%	-19.08%

Apr. 25	Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
2023	Hangzhou Solipharma Technology Development Co., Ltd. announced that it expects to receive CNY 69.4857 million in funding from Sichuan Goldstone Asia Pharmaceutical Inc., Hangzhou Huolongguo Investment Management Co., Ltd. and another investor	CI

Sichuan Goldstone Asia Pharmaceutical Inc. Approves Dividend for the Year 2019

June 22, 2020 at 03:33 pm EDT

Sichuan Goldstone Asia Pharmaceutical Inc. announced at annual general meeting held on June 19, 2020, approved dividend (tax included) of CNY 0.70000000 per ten shares for the year 2019.

Latest news about Sichuan Goldstone Asia Pharmaceutical Inc.

Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Hangzhou Solipharma Technology Development Co., Ltd. announced that it expects to receive CNY 69.4857 million in funding from Sichuan Goldstone Asia Pharmaceutical Inc., Hangzhou Huolongguo Investment Management Co., Ltd. and another investor	Dec. 27	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Approves Management Appointments	Dec. 25	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Sichuan Goldstone Asia Pharmaceutical Inc.(XSEC:300434) added to S&P Global BMI Index	23-09-18	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-24	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-25	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-26	CI
Gao Yaping completed the acquisition of 5.1% shares of Sichuan Goldstone Asia Pharmaceutical Inc. from Kuai Yixi and Yang Xiaodong.	21-09-15	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-26	CI
Gao Yaping signed an equity transfer agreement to acquire 5.1% shares of Sichuan Goldstone Asia Pharmaceutical Inc. from Kuai Yixi and Yang Xiaodong for approximately CNY 170 million.	21-07-29	CI
Sichuan Goldstone Asia Pharmaceutical Inc. signed Equity Acquisition agreement to acquire 65.40% stake in Zhejiang Jiande Zhengfa Pharmaceutical Co.Ltd from group of shareholders for approximately CNY 150 million	21-05-19	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-26	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-21	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Announces Management Changes	20-11-19	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-28	CI
Hangzhou Innovative Chinese Medicine Standardization Research Institute Co., Ltd. announced that it expects to receive CNY 6 million in funding from Sichuan Goldstone Asia Pharmaceutical Inc.	20-10-27	CI
Gao Yaping completed the acquisition of 5% stake in Sichuan Goldstone Asia Pharmaceutical Inc. from Xie Shihuang, Chen Shaojiang and Zhi Ruoyu.	20-10-21	CI
Sichuan Goldstone Asia Pharmaceutical Inc. cancelled the acquisition of Jiangxi JuRenTang Pharmaceutical Company Limited from Hu Liuhe, Liu Min, Hu Xiaoping, and Hu Xuping.	20-10-18	CI
Gao Yaping signed a share transfer agreement to acquire 5% stake in Sichuan Goldstone Asia Pharmaceutical Inc. from Xie Shihuang, Chen Shaojiang and Zhi Ruoyu for approximately CNY 170 million.	20-09-21	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-25	CI

Chart Sichuan Goldstone Asia Pharmaceutical Inc.

Duration

Period

Chart Sichuan Goldstone Asia Pharmaceutical Inc.

More charts

Sichuan Goldstone Asia Pharmaceutical Inc., formerly Sichuan Goldstone Orient New Material Equipment Inc, is a China-based company principally engaged in the production and sales of pharmaceutical products, as well as drug agency business. Its main products include health products, cracks and small cracks. The Company is also engaged in the machinery manufacturing business, as well as property leasing and management business. Its machinery products mainly include steel reinforced plastic pipe production line, bead winding steel reinforced pipe production line, production line equipment parts and other equipment. The Company mainly operates its businesses in domestic market.

Sector

Pharmaceuticals

Calendar

2024-05-24 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SICHUAN GOLDSTONE ASIA PHARMACEUTICAL INC.	-19.08%	503M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+22.35%	44.12B
OTSUKA HOLDINGS CO., LTD.	+22.22%	22.61B
SANDOZ GROUP AG	+17.81%	15.11B
CIPLA LIMITED	+15.73%	13.61B
ZYDUS LIFESCIENCES LIMITED	+57.91%	13.34B
ONO PHARMACEUTICAL CO., LTD.	-8.98%	6.94B
THE MEDICINES COMPANY	-0.05%	6.79B
ASPEN PHARMACARE HOLDINGS LIMITED	+15.65%	5.75B
STADA ARZNEIMITTEL	-8.87%	5.73B

Generic Pharmaceuticals